MedTrace Logo

Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study

NCT05782101 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-09-13

No results posted yet for this study

Summary

The analysis of saliva of preterm newborns could be a powerful tool to investigate human fetal development in an ethically acceptable fashion, indeed the collection of salivary samples is a fast and non-invasive procedure. The purpose of the study is to characterize peptide and proteins present in human preterm saliva and to investigate the relative amount of several proteoforms of the proteins and peptides detectable in preterm saliva in order to have information on the activity of various enzymes acting during late fetal development. Preterm infants with gestational age between 175-216 days (25-30 weeks), admitted to the Neonatal Intensive Care Unit (NICU) will be enrolled for this study. A saliva sample will be collected every seven days from the birthday and up to 40 weeks (286 days) of postmenstrual age (PMA) or up to discharge if it occurs earlier. A targeted ESI mass spectrometry investigation, based on a top-down analysis of the intact salivary proteome will be performed.

Conditions

  • Bronchopulmonary Dysplasia; Retinopathy of Prematurity

Interventions

DIAGNOSTIC_TEST

Integrated proteomic HPLC-ESI-MS analysis of salivary peptides

A targeted ESI mass spectrometry investigation, based on a top-down analysis of the intact salivary proteome will be performed.

Sponsors & Collaborators

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    lead OTHER

Principal Investigators

  • Giovanni Vento, MD · Fondazione Policlinico Universitario A. Gemelli, IRCCS

Eligibility

Max Age
40 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-17
Primary Completion
2023-03-30
Completion
2023-03-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05782101 on ClinicalTrials.gov